- A New Study Research The Relationship Between Specific Drugs and Dementia Diabetes.
- They used data from More than 92,000 People with Type 2 Diabetes.
- The Scientists Found That Two Medications Signantely Reduce The Risk of Developing Dementia in Life.
To New Study, Published in
The Drugs in Question Were Glucagon-Like Peptide-1 Agonist Receiver (LPG-1ras), Like Ozempic and Wegovy, and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is), Like Jardiance.
Specifically, LPG-1ra was Linked to 33% Lower Risk of Dementia, and Sglt2i was Linked to 43% Lower Risk. Other Diabetes Medications, However, Were Not Associated with A Change in Risk.
How are Dementia and Diabetes Linked?
As the average age of the population steadily rises, The Number of Dementia Cases Rises in Step. EVENT DECADES OF INTEVIVE REESARCH, A Cure Rema Elusive. Although Sub Treatments Can Slow Progress, We Are Far From A Breakthrough.
Adding to these challenges, if an effective drarug were Found, It was like many yars to build up a Suficient Evidence Base and Millions of Dollars to Bring it to Market.
For these reasons, submite tendchers are focusing on existing drarugs. If they can identify Drug That is already widely used and helps Lower the risk of dementia, It was a lots shorter Road to Wider Availability.
Som Recent Research You have suggested that Type 2 Diabetes and Dementia May Share Sub Physiological Similarities, Inflamining and Insulin Signalling in the Brain. People with Diabetes Also Have a Higher Risk of Developing Dementia.
This Raises an Interesting Question: If a Drug reduces the impact of type 2 diabetes, might it also reduces The Risk of Dementia? Scientists have now investigated This Question, and submain does suggest that diabetes medication may reduce Dementia Risk.
However, as The Authors of the Latest Study Explain, We Need More Evidence. To Build The Cleareest Picture To Date, They used “A More Rigorous Methodological Approach and Robust Adjustment for Confounding Factors.”
Drugs Like Ozempic Linked To 33% Lower Dementia Risk
To investigate, The Scientists Accessed Data from Florida, Georgia, and Alabama. In Total, This Amount to 92,160 People Anged 50 Or Older With Type 2 Diabetes.
Participants were followed unnil they died or developed dementia, including Alzheimer’s, vascular dementia, frontotemporal dementia, and lewy body dementia.
They focused on three comparisons:
- LPG-1RA versus oher second-line glucose-lowering drarugs
- SGLT2I versus OHER Second-LINE GLUCOSE-LOWERING DRUGS
- LPG-1RA versus SGLT2I.
The Scientists Concluded That GLP-1ras and Sglt2is were Associated with A Reded Risk of Developing Dementias Comparced with Second-Line Drugs Diabetes.
“LPG-1RA USE was Associated with at 33% Lower Risk of (Dementia), While Sglt2i uses was Associated with at 43% Lower Risk Compared with Other (Glucose-Lowering Drugs),” The Authors Write.
Medical News Today Contact William Kapp, MD, Longevity Expert and Ceo of Fountain Life, Not Involved in Tis Study.
Kapp Shared His Thoughts on The Findings, Saying:
“The Results Didn’t Shock Me – But They Did Give More Credence To What We’ve Been Observing. Brain and Body Don’t Age Separately. Metabolic Problems Such As Insulin Resistance Are Linked to Inflammation, Oxidative Stress, and Altered Blood Flow – All of Which impact Brain Health.”
How do these drarug reduces Dementia Risk?
Although Scientists do not know for southern Howlp-1ra and Sglt2i May reduces Dementia Risk in People with Type 2 Diabetes, The Authors Suggest Sub Bes Potential Mechanisms.
For Instance, LPG-1ras have shown to:
- reduces neuroinflamation
- Improve
Insulin Signalling in the Brain - Promote The Growth of New Nerve Cells (Neurogenesis).
Similarly, sglt2is may protect the brain by:
- Blood Flow brain improving
- Reductive oxidative stress
- Enhancing Mithochondrial Activity.
The Scientists Also Explain That Drugs Are Associated With Improved Metabolic and Vascular Health, Both of Which May Support Healthy Brain Function.
Additionionally, there is submissive that that is drarugs can reduces Levels of Amyloid-Beta and Tau Proteins in the Brain-The Hallmarks of Alzheimer’s Disease.
Speaking with the Science Media Center, Prof. David Strain, MD, FRCP, Associate Professor of Cardiometabolic Health at the University of Exeter Medical School in the United Kingdom, similarly not Involved in the Study, explained that:
“GLP-1 receiver Antagonists and Sglt-2 inhibitors have Been Demonstated to Control The Sugar, and Also Reduces The Inflammation (a Key Driver of Alzheimer’s Disease) and reduces vascular Risk (a Key Driver of Vascular Dementia) More than Would Be Expected by The Sugar Control Alone.”
“It is Therefore no Surprise That these data show to Lower Risk of Dementia in People Who Reive Them As Part of Her Routine Care,” Strain Continued.
Do we have angouch data to draw strong conclusions?
This Study, Which Analyzed Data from Almost 100,000 People is Supported by A Number of Previous Studies. However, Paper Published in the Same Journal and on The Same Day Casts a Small Portion of Doubt On The Results.
The Paper in Question, Also Published in
ACCORDING TO ITS AUTHORS, “Glucose-Lowering Therapy with GLP1-RAS, But Not Sglt2is, was associated with a Statistics significant reduction in dementia or cognitive unpaid.”
So, The Conclusions on LPG1-RAS Mirror Those From The Original Paper, But They Did Not Find The Same Effect for Sglt2is. This May Be Partly Due to the Short Duration of Follow-Up. The Average Study Follow-Up in the Meta-Analysis and the Follow-Up in the original Study Were Under 5 Years.
As Dementia Takes Many Years To Develop, This May Not Be Long Enough.
“It’s Still Early, and We’re Still Not Seeing All The Long-Term Data,” Kapp Told MNT. But what we’re seeing is that regulating insulin and inflammation might also slown subm of the changes in the brain tied to dementia. ”
The inevitable Next Question Is: Will these Drugs reduces Dementia Risk in People Without Diabetes?
“If the benefit is From Reducting insulin resistance or inflammation, it’s possible that before Drugs could be Good for People Without Diabetes,” Kapp Told MNT BEFORE INJECTING SOME CAUTION.
“Just Because Something is Good for One Group Doesn’t Mean it is for other.
For Now, The Jury Is – At Least in Part – Out. We May have to wait for longer studies Before we can draw solid conclusions. Still, it is looking increasingly Likely that glp1-ras might reduces the Risk of Dementia for People with Type 2 Diabetes, which is certainty to positive finding.
